Terms: = Colorectal cancer AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1 AND Clinical Outcome
19 results:
1. Efficacy of the Oral Administration of Maltodextrin Fructose Before Major Abdominal Surgery: A Prospective, Multicenter clinical Study.
Qin H; Ji J; Miao Y; Liu T; Zhao D; Jia Z; Jiang J; Liu J; Li Q; Ji X; Fu W; Lou D; Xia W; Li N
World J Surg; 2022 Sep; 46(9):2132-2140. PubMed ID: 35718790
[TBL] [Abstract] [Full Text] [Related]
2. Applicability of five nutritional screening tools in Chinese patients undergoing colorectal cancer surgery: a cross-sectional study.
Xie B; Sun Y; Sun J; Deng T; Jin B; Gao J
BMJ Open; 2022 May; 12(5):e057765. PubMed ID: 35623749
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic Significance of Patient-Reported outcomes in cancer.
Kerrigan K; Patel SB; Haaland B; Ose D; Weinberg Chalmers A; Haydell T; Meropol NJ; Akerley W
JCO Oncol Pract; 2020 Apr; 16(4):e313-e323. PubMed ID: 32048943
[TBL] [Abstract] [Full Text] [Related]
4. Hyperspectral imaging for tissue classification, a way toward smart laparoscopic colorectal surgery.
Baltussen EJM; Kok END; Brouwer de Koning SG; Sanders J; Aalbers AGJ; Kok NFM; Beets GL; Flohil CC; Bruin SC; Kuhlmann KFD; Sterenborg HJCM; Ruers TJM
J Biomed Opt; 2019 Jan; 24(1):1-9. PubMed ID: 30701726
[TBL] [Abstract] [Full Text] [Related]
5. A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis.
Kim SY; Baek JY; Oh JH; Park SC; Sohn DK; Kim MJ; Chang HJ; Kong SY; Kim DY
Radiat Oncol; 2017 Mar; 12(1):62. PubMed ID: 28347333
[TBL] [Abstract] [Full Text] [Related]
6. A rare case of extremely high counts of circulating tumor cells detected in a patient with an oral squamous cell carcinoma.
Wu X; Mastronicola R; Tu Q; Faure GC; De Carvalho Bittencourt M; Dolivet G
BMC Cancer; 2016 Jul; 16():552. PubMed ID: 27465596
[TBL] [Abstract] [Full Text] [Related]
7. Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer.
Elez E; Hendlisz A; Delaunoit T; Sastre J; Cervantes A; Varea R; Chao G; Wallin J; Tabernero J
Br J Cancer; 2016 Feb; 114(4):372-80. PubMed ID: 26766738
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract] [Full Text] [Related]
9. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.
Van Cutsem E; Tejpar S; Vanbeckevoort D; Peeters M; Humblet Y; Gelderblom H; Vermorken JB; Viret F; Glimelius B; Gallerani E; Hendlisz A; Cats A; Moehler M; Sagaert X; Vlassak S; Schlichting M; Ciardiello F
J Clin Oncol; 2012 Aug; 30(23):2861-8. PubMed ID: 22753904
[TBL] [Abstract] [Full Text] [Related]
10. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
Kim SY; Shim EK; Yeo HY; Baek JY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Jung KH; Chang HJ
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):201-7. PubMed ID: 22672749
[TBL] [Abstract] [Full Text] [Related]
11. First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study.
Sastre J; Grávalos C; Rivera F; Massuti B; Valladares-Ayerbes M; Marcuello E; Manzano JL; Benavides M; Hidalgo M; Díaz-Rubio E; Aranda E
Oncologist; 2012; 17(3):339-45. PubMed ID: 22363067
[TBL] [Abstract] [Full Text] [Related]
12. clinical usefulness of mitochondrial transcription factor A expression as a predictive marker in colorectal cancer patients treated with FOLFOX.
Yoshida Y; Hasegawa J; Nezu R; Kim YK; Hirota M; Kawano K; Izumi H; Kohno K
Cancer Sci; 2011 Mar; 102(3):578-82. PubMed ID: 21205083
[TBL] [Abstract] [Full Text] [Related]
13. [clinical features of hypersensitivity reactions to oxaliplatin among Chinese colorectal cancer patients].
Zhao Y; An X; Xiang XJ; Feng F; Wang FH; Wang ZQ; Xu RH; He YJ; Li YH
Chin J Cancer; 2010 Jan; 29(1):102-5. PubMed ID: 20038320
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract] [Full Text] [Related]
15. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial).
Correale P; Tagliaferri P; Fioravanti A; Del Vecchio MT; Remondo C; Montagnani F; Rotundo MS; Ginanneschi C; Martellucci I; Francini E; Cusi MG; Tassone P; Francini G
Clin Cancer Res; 2008 Jul; 14(13):4192-9. PubMed ID: 18593999
[TBL] [Abstract] [Full Text] [Related]
16. Preoperative UFT administration for patients with advanced colorectal cancer--increased uptake of 5-fluorouracil by tumor tissue is a prognostic factor.
Nakagoe T; Ishikawa H; Sawai T; Tsuji T; Ayabe H; Eida K; Nogawa T; Nakamura Y; Kunisaki T; Tobinaga K; Furukawa M; Ino M
Anticancer Drugs; 2000 Mar; 11(3):155-63. PubMed ID: 10831274
[TBL] [Abstract] [Full Text] [Related]
17. Pre-operative IL-2 immunoprophylaxis of cancer recurrence: long-term clinical results of a phase II study in radically operable colorectal cancer.
Brivio F; Lissoni P; Fumagalli L; Girlando M; Marsili MT; Nespoli A; Uggeri F
Oncol Rep; 1999; 6(6):1205-7. PubMed ID: 10523681
[TBL] [Abstract] [Full Text] [Related]
18. The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b.
Tsavaris N; Baxevanis C; Kosmidis P; Papamichael M
Cancer Immunol Immunother; 1996 Oct; 43(2):94-102. PubMed ID: 8954143
[TBL] [Abstract] [Full Text] [Related]
19. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer.
Itzkowitz SH; Yuan M; Montgomery CK; Kjeldsen T; Takahashi HK; Bigbee WL; Kim YS
Cancer Res; 1989 Jan; 49(1):197-204. PubMed ID: 2908846
[TBL] [Abstract] [Full Text] [Related]
